CRISPR Therapeutics

CRISPR Therapeutics CRSP Stock

$40.12   -0.161728%
Add to favorites
Market Cap
$3.89B
LOW - HIGH [24H]
$39.50 - $41.63
VOLUME [24H]
$1.42M
P/E Ratio
0
Earnings per share
-$4.73
ISIN
CH0334081137
Price   Prediction

CRISPR Therapeutics Price Chart

Sorry, that's all we've gotfor now...

CRISPR Therapeutics (CRSP) stock price today is 40.13 USD on Tech Market Middle (-0.16% on the day). Updated .

CRISPR Therapeutics CRSP Financial and Trading Overview

CRISPR Therapeutics stock price 40.13 USD
Previous Close 40.15 USD
Open 40.25 USD
Bid 44.5 USD x 100
Ask 67.84 USD x 200
Day's Range 40.1 - 42.66 USD
52 Week Range 39.8 - 63.45 USD
Volume 3.97M USD
Avg. Volume 1.71M USD
Market Cap 3.9B USD
Beta (5Y Monthly) 1.897
PE Ratio (TTM) N/A
EPS (TTM) -4.73 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 85.42 USD

CRSP Valuation Measures

Enterprise Value 2.41B USD
Trailing P/E N/A
Forward P/E -10.90611
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 154.87299
Price/Book (mrq) 2.3618946
Enterprise Value/Revenue 95.572
Enterprise Value/EBITDA -4.815

Trading Information

CRISPR Therapeutics Stock Price History

Beta (5Y Monthly) 1.897
52-Week Change -20.85%
S&P500 52-Week Change 10.51%
52 Week High 63.45 USD
52 Week Low 39.8 USD
50-Day Moving Average 51.49 USD
200-Day Moving Average 52.42 USD

CRSP Share Statistics

Avg. Volume (3 month) 1.71M USD
Avg. Daily Volume (10-Days) 2.34M USD
Shares Outstanding 97M
Float 96.49M
Short Ratio 11.65
% Held by Insiders 5.31%
% Held by Institutions 78.02%
Shares Short 17.19M
Short % of Float 20.28%
Short % of Shares Outstanding 17.71%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -2058.54%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -13.48%
Return on Equity (ttm) -25.59%

Income Statement

Revenue (ttm) 25.17M USD
Revenue Per Share (ttm) 0.26 USD
Quarterly Revenue Growth (yoy) 1325.09%
Gross Profit (ttm) -447176000 USD
EBITDA -499680000 USD
Net Income Avi to Common (ttm) -456135008 USD
Diluted EPS (ttm) -4.73
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.27B USD
Total Cash Per Share (mrq) 23.43 USD
Total Debt (mrq) 779.83M USD
Total Debt/Equity (mrq) 47.32 USD
Current Ratio (mrq) 16.211
Book Value Per Share (mrq) 17.016

Cash Flow Statement

Operating Cash Flow (ttm) -374632000 USD
Levered Free Cash Flow (ttm) -215401248 USD

Profile of CRISPR Therapeutics

Country United States
State N/A
City Zug
Address Baarerstrasse 14
ZIP 6300
Phone 41 41 561 32 79
Website https://www.crisprtx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees N/A

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Q&A For CRISPR Therapeutics Stock

What is a current CRSP stock price?

CRISPR Therapeutics CRSP stock price today per share is 40.13 USD.

How to purchase CRISPR Therapeutics stock?

You can buy CRSP shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for CRISPR Therapeutics?

The stock symbol or ticker of CRISPR Therapeutics is CRSP.

Which industry does the CRISPR Therapeutics company belong to?

The CRISPR Therapeutics industry is Biotechnology.

How many shares does CRISPR Therapeutics have in circulation?

The max supply of CRISPR Therapeutics shares is 97M.

What is CRISPR Therapeutics Price to Earnings Ratio (PE Ratio)?

CRISPR Therapeutics PE Ratio is now.

What was CRISPR Therapeutics earnings per share over the trailing 12 months (TTM)?

CRISPR Therapeutics EPS is -4.73 USD over the trailing 12 months.

Which sector does the CRISPR Therapeutics company belong to?

The CRISPR Therapeutics sector is Healthcare.

CRISPR Therapeutics CRSP included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 24201.34 USD —
-0.94
4.68B USD — 24005.47 USD — 24939.62 USD — — 4.68B USD —
us US Tech Global Market Composite NQGM US 1835.64 USD —
-0.18
— — 1820.49 USD — 1866.97 USD — — — —
us US Tech DM Ex Japan Large Mid Ca NQDMXJPLMAUD US 2100.38 AUD 1467.26 USD
<0.01
— — 2100.38 AUD 1467.26 USD 2100.38 AUD 1467.26 USD — — —
us US Tech Biotechnology NBI US 6965.89 USD —
-0.08
— — 6905.76 USD — 7033.67 USD — — — —
us US Tech Health Care IXHC US 1317.49 USD —
-0.52
— — 1309.03 USD — 1333.62 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3605.34 USD —
-0.97
— — 3577.02 USD — 3690.74 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
$2.17T
Total marketcap
$71.79B
Total volume
BTC 58.07%   •   ETH 9.95%
Dominance
Select currency